BONUS INTERVIEW: Prof. Dr. Jörn M. Schattenberg and Roger Green spend 20 minutes discussing Joern’s reaction to the January 29 FDA Webcast. Joern discusses why digital pathology is such a benefit to trial sites outside the US and some of the new clinical development and sample size considerations emanating from a need to provide more robust safety data. An interesting, informative conversation.